Billiontoone (NASDAQ:BLLN) Announces Earnings Results

Billiontoone (NASDAQ:BLLN) announced its quarterly earnings results on Wednesday. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07, Briefing.com reports. Billiontoone’s quarterly revenue was up 113.0% compared to the same quarter last year.

Here are the key takeaways from Billiontoone’s conference call:

• Financial outperformance: BillionToOne reported 100% year‑over‑year revenue growth for 2025 (Q4 revenue $96.1M, +113% YoY), an annualized run‑rate of $384M, GAAP profitability for Q4 and full year, and a strong balance sheet with ~$496M cash versus ~$50M term debt.
• Product and reimbursement catalysts: The company launched expanded prenatal offerings (including the first platelet fetal‑antigen NIPT), oncology add‑ons (Northstar PGx and CH), submitted Northstar Response to MolDx, and signed an in‑network contract with UnitedHealthcare, all of which could accelerate volume and ASPs.
• Improving unit economics and margins: ASPs rose sharply (2025 ASP $495; Q4 ASP $561), COGS per test declined, gross margin reached 71.4% in Q4, and operating/adjusted EBITDA margins turned positive, reflecting higher efficiency and automation.
• Key risks and conservative assumptions: 2026 guidance ($430M–$445M) excludes potential upside from United and health‑system EMR integrations, MolDx coverage for Northstar Response is still pending, and results remain sensitive to payer coverage, mix shifts to oncology, and true‑up variability.

Billiontoone Price Performance

Shares of Billiontoone stock traded down $2.31 during trading on Wednesday, reaching $80.83. The company’s stock had a trading volume of 392,982 shares, compared to its average volume of 245,757. The stock has a 50-day moving average of $86.15. Billiontoone has a one year low of $66.00 and a one year high of $138.70. The firm has a market capitalization of $3.70 billion and a PE ratio of 808.30.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. T. Rowe Price Investment Management Inc. acquired a new position in Billiontoone during the 4th quarter valued at about $8,277,000. Invesco Ltd. acquired a new position in Billiontoone during the fourth quarter valued at approximately $15,535,000. XTX Topco Ltd bought a new stake in Billiontoone in the fourth quarter valued at approximately $1,692,000. Quadrature Capital Ltd acquired a new stake in Billiontoone in the fourth quarter worth $614,000. Finally, Perceptive Advisors LLC bought a new position in shares of Billiontoone during the fourth quarter worth $5,959,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Weiss Ratings started coverage on Billiontoone in a report on Tuesday, February 3rd. They set a “sell (d)” rating on the stock. Wall Street Zen upgraded Billiontoone to a “hold” rating in a research report on Saturday, November 15th. Zacks Research upgraded Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus started coverage on Billiontoone in a research note on Monday, December 1st. They set a “buy” rating and a $145.00 price objective for the company. Finally, Wells Fargo & Company started coverage on Billiontoone in a report on Monday, December 1st. They set an “equal weight” rating and a $110.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $135.29.

Billiontoone News Summary

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat expectations — BillionToOne reported $0.11 EPS vs. consensus $0.04 and revenue +113% year-over-year, signaling robust top-line growth and margin improvement. GlobeNewswire: Q4 and FY2025 Results
• Positive Sentiment: Raised FY2026 revenue guidance — management now expects roughly $430M–$445M in revenue for 2026 versus a prior consensus near $356M, implying accelerated growth expectations that justify a higher valuation multiple if execution continues. GlobeNewswire: Guidance Raise
• Neutral Sentiment: Analyst/metrics write-ups — Zacks and other outlets published analysis comparing BLLN’s quarter and key metrics to estimates; useful for drill-down but not new company guidance. Zacks: Q4 Metrics vs. Estimates
• Neutral Sentiment: Earnings snapshot coverage — local/business outlets summarized the quarter; helpful context but no fresh catalysts beyond the company release. LMT Online: Q4 Snapshot
• Neutral Sentiment: Short-interest reporting appears anomalous — several reports show a “large increase” but list zero shares and NaN changes; data looks unreliable and should not be treated as a clear short-pressure signal until exchanges/clearing firms reconcile the figures.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.